Literature DB >> 17196264

Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography.

Guang Qu1, Jennifer Bahr-Davidson, Joseph Prado, Alex Tai, Floro Cataniag, Jennifer McDonnell, Jingmin Zhou, Bernd Hauck, Jac Luna, Jurg M Sommer, Peter Smith, Shangzhen Zhou, Peter Colosi, Katherine A High, Glenn F Pierce, J Fraser Wright.   

Abstract

Adeno-associated virus (AAV) empty capsids typically co-purify with genome containing AAV2 vectors purified by column chromatography. This study describes a method to remove empty capsids from genome containing vector particles by anion exchange chromatography. The separation is based on the slightly less anionic character of empty particles compared to vectors. Detailed methods to achieve AAV2 vector purification and particle separation using cation exchange resin POROS 50HS followed by anion exchange resin Q-Sepharose(xl) are described. Chromatographic separation of AAV2 particles was achieved using gradients based on sodium acetate and ammonium acetate, and was optimal at pH 8.5. Efficient removal of particle surface nucleic acid impurities was found to be important to achieve good particle separation. In a large scale experiment performed using partially purified vector containing a mixture of 1.56 x 10(14)vg and 2.52 x 10(15) empty capsids as a starting material, the optimized anion exchange chromatography method resulted in a vector peak of 1.15 x 10(14)vg containing 0.25 x 10(14) empty capsids, corresponding to 74% vector yield and 86-fold reduction in empty capsids in the vector product.

Entities:  

Mesh:

Year:  2006        PMID: 17196264     DOI: 10.1016/j.jviromet.2006.11.019

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  41 in total

Review 1.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

2.  Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

Authors:  Bernd Hauck; Samuel L Murphy; Peter H Smith; Guang Qu; Xingge Liu; Olga Zelenaia; Federico Mingozzi; Jürg M Sommer; Katherine A High; J Fraser Wright
Journal:  Mol Ther       Date:  2008-10-21       Impact factor: 11.454

3.  Analysis of particle content of recombinant adeno-associated virus serotype 8 vectors by ion-exchange chromatography.

Authors:  Martin Lock; Mauricio R Alvira; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2012-02       Impact factor: 2.396

4.  Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy.

Authors:  Stifani Satkunanathan; Jun Wheeler; Robin Thorpe; Yuan Zhao
Journal:  Hum Gene Ther       Date:  2014-09-11       Impact factor: 5.695

5.  Filling Adeno-Associated Virus Capsids: Estimating Success by Cryo-Electron Microscopy.

Authors:  Suriyasri Subramanian; Anna C Maurer; Carol M Bator; Alexander M Makhov; James F Conway; Kevin B Turner; James H Marden; Luk H Vandenberghe; Susan L Hafenstein
Journal:  Hum Gene Ther       Date:  2019-11-14       Impact factor: 5.695

6.  Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.

Authors:  Chengwen Li; Yi He; Sarah Nicolson; Matt Hirsch; Marc S Weinberg; Ping Zhang; Tal Kafri; R Jude Samulski
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

7.  The Jeremiah Metzger Lecture: gene therapy for inherited disorders: from Christmas disease to Leber's amaurosis.

Authors:  Katherine A High
Journal:  Trans Am Clin Climatol Assoc       Date:  2009

Review 8.  Transient transfection methods for clinical adeno-associated viral vector production.

Authors:  J Fraser Wright
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

9.  Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.

Authors:  Gary C Pien; Etiena Basner-Tschakarjan; Daniel J Hui; Ashley N Mentlik; Jonathan D Finn; Nicole C Hasbrouck; Shangzhen Zhou; Samuel L Murphy; Marcela V Maus; Federico Mingozzi; Jordan S Orange; Katherine A High
Journal:  J Clin Invest       Date:  2009-05-11       Impact factor: 14.808

Review 10.  Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer.

Authors:  Sander W Tas; Margriet J B M Vervoordeldonk; Paul P Tak
Journal:  Curr Gene Ther       Date:  2009-06       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.